Kaleido Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Kaleido Biosciences

04/05/2021 16:43

* Kaleido Biosciences Inc  KLDO.OQ  reported a quarterly
adjusted loss of 58 cents​​ per share for the quarter ended
in March. The mean expectation of six analysts for the quarter
was for a loss of 59 cents per share.
* Revenue was $297.00 thousand​​;  analysts expected $0.00.
* Kaleido Biosciences Inc's reported EPS for the quarter was a
loss of 58 cents​.
* The mean earnings estimate of analysts had fallen by
about 41.4% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Kaleido Biosciences Inc shares had fallen by 9.1% this
quarter and lost 19.1% so far this year.
* The company reported a quarterly loss of $23.04 million.
* Wall Street's median 12-month price target for Kaleido
Biosciences Inc is $15.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
This summary was machine generated May 4 at 03:42 p.m. GMT. ​All
figures in US Dollars.​